Outstanding 12-month first-in-human data from Xeltis’ aXess hemodialysis vascular conduit trial presented at VEITHsymposium 2023 Outstanding 12-month first-in-human data from Xeltis’ aXess hemodialysis vascular conduit trial presented at VEITHsymposium 2023 aXess demonstrated exceptional patency rates and no infections to date...

Xeltis secures additional €12.5 million from European Innovation Council Fund in final close of D2 financing Xeltis secures additional €12.5 million from European Innovation Council Fund in final close of D2 financing Funding extends Xeltis’ Series D2 financing round to €44.5 million EINDHOVEN, The...

Xeltis presents excellent six-month first-in-human data from aXess hemodialysis vascular graft trial at Vascular Access Society Congress Xeltis presents excellent six-month first-in-human data from aXess hemodialysis vascular graft trial at Vascular Access Society Congress aXess graft demonstrated excellent patency, low rates of...

Xeltis raises €32 million to drive clinical development of world’s most advanced restorative cardiovascular devices Xeltis raises €32 million to drive clinical development of world’s most advanced restorative cardiovascular devices New investors DaVita Venture Group and Invest-NL join syndicate of international...